{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:36:09Z","timestamp":1754156169085,"version":"3.41.2"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n               Purpose To analyse real-world clinical outcomes and influence of the spherical equivalent (SE) on anti-vascular endothelial growth factor (VEGF) therapy in patients affected by myopic choroidal neovascularisation (mCNV).<\/jats:p><jats:p>\n               Patients and Methods A retrospective investigation was conducted on treatment-na\u00efve mCNV patients receiving anti-VEGF therapy at the Department of Ophthalmology, University Medical Center Mainz, Germany, between January 2018 and March 2024. Safety, functional and morphological changes in visual acuity (VA), central retinal thickness (CRT), and central retinal volume (CRV) were evaluated over a two-year period. Further, we analysed how baseline VA and CRT relate to it\u02bcs final outcome measures. Finally, a subgroup analysis assessed the impact of SE above and below \u2212\u200910\u2009D.<\/jats:p><jats:p>\n               Results Significant improvements in VA, CRT, and CRV were observed. VA improved from 0.5\u2009\u00b1\u20090.27 logMAR to 0.38\u2009\u00b1\u20090.31 logMAR (p\u2009=\u20090.005) at 6 months and remained stable at 2 years. CRT and CRV decreased from 344.4\u2009\u00b1\u2009115.0\u2009\u00b5m to 284.2\u2009\u00b1\u200945.2\u2009\u00b5m (p\u2009&lt;\u20090.001) and 0.27\u2009\u00b1\u20090.09\u2009mm\u00b3 to 0.22\u2009\u00b1\u20090.04\u2009mm\u00b3 (p\u2009&lt;\u20090.001), respectively, four weeks after the initial injection, with stability maintained thereafter. Baseline VA correlated strongly with final VA, whereas CRT did not. No adverse events were reported. The subgroup analysis showed no significant outcome differences based on SE.<\/jats:p><jats:p>\n               Conclusion Anti-VEGF therapy in mCNV patients proved to be safe and effective in our study with sustained improvement in functional and anatomical measures. Baseline VA strongly predicted final VA, whereas baseline and final CRT showed no association. No differences in treatment outcomes were observed as based on a varying SE.<\/jats:p>","DOI":"10.1055\/a-2561-2847","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:29:50Z","timestamp":1749670190000},"page":"745-751","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Efficacy, Safety, and the Impact of Spherical Equivalent on Intravitreal Anti-VEGF Therapy in Patients Affected by Myopic Choroidal Neovascularisation"],"prefix":"10.1055","volume":"242","author":[{"given":"Peter","family":"Wolfrum","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Voigt","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard M.","family":"Stoffelns","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Korb","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Centre of the Johannes Gutenberg University Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4395278","DOI":"10.1155\/2020\/4395278","article-title":"Recent Epidemiology Study Data of Myopia","volume":"2020","author":"Z Y Xiang","year":"2020","journal-title":"J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050","volume":"123","author":"B A Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/bjophthalmol-2015-307724","article-title":"Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention","volume":"100","author":"A R Rudnicka","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00347-017-0601-0","article-title":"[Analysis of spectacle lens prescriptions shows no increase of myopia in Germany from 2000 to 2015]","volume":"115","author":"W Wesemann","year":"2018","journal-title":"Ophthalmologe"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3238\/arztebl.2020.0855","article-title":"Prevalence and Time Trends in Myopia Among Children and Adolescents","volume":"117","author":"A K Schuster","year":"2020","journal-title":"Dtsch Arztebl Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/s-0043-102938","article-title":"[Prevalence and Risk Factors of Myopia in Children and Adolescents in Germany \u2013 Results of the KiGGS Survey]","volume":"229","author":"A K Schuster","year":"2017","journal-title":"Klin Padiatr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ophtha.2020.07.017","article-title":"Evolution of the Prevalence of Myopia among Taiwanese Schoolchildren: A Review of Survey Data from 1983 through 2017","volume":"128","author":"T H Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1167\/iovs.13-13029","article-title":"Seasonal variations in the progression of myopia in children enrolled in the correction of myopia evaluation trial","volume":"55","author":"J Gwiazda","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"65.e1","DOI":"10.1016\/j.jaapos.2021.11.014","article-title":"Rapid progression of myopia at onset during home confinement","volume":"26","author":"C Picotti","year":"2022","journal-title":"J AAPOS"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ajo.2020.07.034","article-title":"Digital Screen Time During the COVID-19 Pandemic: Risk for a Further Myopia Boom?","volume":"223","author":"C W Wong","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"101246","DOI":"10.1016\/j.preteyeres.2024.101246","article-title":"Optic neuropathy in high myopia: Glaucoma or high myopia or both?","volume":"99","author":"X Zhang","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"ref12","first-page":"269","volume-title":"Chapter 14 \u2013 Acquired Macular Disorders","author":"J F Salmon","year":"2023"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.35772\/ghm.2020.01007","article-title":"Pathologic myopia: an overview of the current understanding and interventions","volume":"2","author":"T Ueta","year":"2020","journal-title":"Glob Health Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/icl.0000000000000201","article-title":"Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia","volume":"42","author":"N S Chan","year":"2016","journal-title":"Eye Contact Lens"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"S Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study","volume":"122","author":"Y Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/s0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"R W Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1055\/a-0589-6449","article-title":"Stellungnahme des Berufsverbandes der Augen\u00e4rzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Therapie choroidaler Neovaskularisationen bei anderen Erkrankungen als der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration","volume":"235","author":"Berufsverband der Augen\u00e4rzte Deutschlands e.V.","year":"2018","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2147\/opth.S311816","article-title":"Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization","volume":"15","author":"D Bhatia","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e0227557","DOI":"10.1371\/journal.pone.0227557","article-title":"Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study","volume":"15","author":"R D Hamilton","year":"2020","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40123-024-00901-6","article-title":"Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data","volume":"13","author":"A K Schuster","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.18553\/jmcp.2020.19245","article-title":"Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema","volume":"26","author":"S Kiss","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/bjophthalmol-2016-308668","article-title":"Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV","volume":"101","author":"T Wecker","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/kjm2.12669","article-title":"Optical coherence tomography biomarkers for myopic choroidal neovascularization treated with anti-vascular endothelial growth factor","volume":"39","author":"D Y Lee","year":"2023","journal-title":"Kaohsiung J Med Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1097\/iae.0000000000000610","article-title":"Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"35","author":"D S Ng","year":"2015","journal-title":"Retina"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12886-021-02088-x","article-title":"Result of intravitreal aflibercept injection for myopic choroidal neovascularization","volume":"21","author":"S L Chen","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1038\/s41598-022-10961-y","article-title":"Baseline predictors for good visual gains after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization","volume":"12","author":"C R Hsu","year":"2022","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/eye.2015.199","article-title":"Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study","volume":"30","author":"C Bru\u00e8","year":"2016","journal-title":"Eye (Lond)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/IAE.0b013e31821ba2dc","article-title":"Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization","volume":"31","author":"J Z Kuo","year":"2011","journal-title":"Retina"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00417-023-06271-2","article-title":"Treatment of myopic choroidal neovascularization: a network meta-analysis and review","volume":"262","author":"L Glachs","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2561-2847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T22:30:24Z","timestamp":1753396224000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2561-2847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":30,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2025,7,24]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2561-2847","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}